Products
Velpatasvir was approved in 2016 in fixed combination with the HCV polymerase inhibitor sofosbuvir in film-coated tablet form (Epclusa, Gilead). Another fixed combination is Vosevi with sofosbuvir and voxilaprevir.
Structure and properties
Velpatasvir (C49H54N8O8, Mr = 883.0 g/mol)
Effects
Velpatasvir has antiviral properties. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other HCV antiviral drugs, this is not an enzyme but a phosphoprotein that plays a role in RNA replication and assembly.
Indications
In combination with sofosbuvir for the treatment of chronic hepatitis C (genotype 1 to 6).
Dosage
According to the SmPC. Tablets are taken once daily, independent of meals.
Contraindications
- Hypersensitivity
- Combination with strong P-gp or CYP450 inducers.
For complete precautions, see the drug label.
Interactions
Velpatasvir is a substrate of P-glycoprotein and BCRP as well as CYP450 isoenzymes (CYP2B6, CYP2C8, CYP3A4). Corresponding drug-drug interactions are possible.
Adverse effects
The most common possible adverse effects include fatigue, headache, and nausea.
